GlassScriptPhysician profile
David J Pernikoff
NPI 1205820594
$17,201.73
in general payments reported to CMS, 2019-2025
59 companies · $2,230 in 2025
The $2,230 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,644 · 2020: $1,934 · 2021: $3,402 · 2022: $2,696 · 2023: $2,320 · 2024: $1,975 · 2025: $2,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,505 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,505.48 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,170.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,945.50 | 2021-2025 | |
| Lilly USA, LLC | $1,631.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,282.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $956.66 | 2020-2025 | Rexulti, Abilify Maintena |
| Amarin Pharma, INC. | $919.58 | 2019-2022 | |
| Pfizer INC. | $888.63 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $839.05 | 2019-2024 | Xarelto |
| Amgen INC. | $661.52 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.44 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $444.17 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $391.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $352.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $341.50 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $296.43 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pernikoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.